We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

5801:TSEFurukawa Electric Co., Ltd. Analysis

Data as of 2026-06-13 - not real-time

¥42,090.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Furukawa Electric (5801.T) has delivered an extraordinary price rally, up roughly 320% year‑to‑date and 50% in the last 30 days, propelling the stock into the upper half of its 52‑week range (current ¥42,090 vs. high ¥62,410). However, the momentum is now confronting several headwinds: the price sits well below the 20‑day (¥50,462) and 50‑day (¥46,277) moving averages, the MACD is in a bearish crossover with a negative histogram, and trading volume is trending down, suggesting waning buying pressure.
Fundamentally, the company posts solid top‑line growth (≈12% revenue increase) and a respectable ROE (~19%), yet it trades at a steep P/E of about 41 versus an industry average of 31, and a P/B of 7.1, indicating significant overvaluation. The balance sheet is levered (debt‑to‑equity ~76) and cash flow generation is modest relative to debt, while the dividend yield is only 0.05% with a 20% payout, raising questions about dividend sustainability. High beta (≈1.2) and extreme 30‑day volatility (≈104%) amplify market risk, especially in a cyclical industrials sector. Overall, the stock’s recent gains appear price‑driven rather than fundamentals‑driven, warranting cautious positioning.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price well below short‑term moving averages
  • Bearish MACD and decreasing volume
  • Extreme short‑term volatility and high beta

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Solid revenue growth and decent ROE
  • Continued overvaluation relative to peers
  • High leverage and modest free cash flow

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Diversified product portfolio across infrastructure and electronics
  • Potential for earnings improvement if debt is reduced
  • Valuation risk remains until price corrects toward fundamentals

Key Metrics & Analysis

Financial Health

Revenue Growth12.20%
Profit Margin5.55%
P/E Ratio40.8
ROE18.77%
ROA3.89%
Debt/Equity75.68
P/B Ratio7.1
Op. Cash Flow¥28.1B
Free Cash Flow¥5.1B
Industry P/E30.6

Technical Analysis

TrendBullish
RSI40.2
Support¥38,080.00
Resistance¥62,410.00
MA 20¥50,461.50
MA 50¥46,276.50
MA 200¥21,821.27
MACDBearish
VolumeDecreasing
Fear & Greed Index89.86

Valuation

Target Price¥65,577.78
Upside/Downside55.80%
GradeOvervalued
TypeBlend
Dividend Yield0.05%

Risk Assessment

Beta1.20
Volatility104.38%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.